• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新冠病毒病:一种由蛋白酶/抗蛋白酶失衡驱动的疾病?大流行五年后的专题综述

COVID-19: A Disease Driven by Protease/Antiprotease Imbalance? A Specific Review Five Years into the Pandemic.

作者信息

Di Micco Pierpaolo, Siniscalchi Carmine, Imbalzano Egidio, Russo Vincenzo, Camporese Giuseppe, Lodigiani Corrado, Meschi Tiziana, Perrella Alessandro

机构信息

UOC Medicina Interna, AFO Medica, P.O. Santa Maria delle Grazie, Pozzuoli (NA), ASL Napoli 2 Nord, CAP 80076, Italy.

Internal Medicine Department, Parma University Hospital, Parma, Italy.

出版信息

Infect Drug Resist. 2025 Aug 8;18:3967-3975. doi: 10.2147/IDR.S541205. eCollection 2025.

DOI:10.2147/IDR.S541205
PMID:40799952
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12341827/
Abstract

COVID-19, caused by SARS-CoV-2, has profoundly impacted global health since late 2019. Beyond respiratory complications, the disease involves systemic manifestations driven by immune dysregulation, inflammation, and coagulopathy. Among the many mechanisms implicated in severe disease, a growing body of evidence suggests a central role for the imbalance between proteases and antiproteases. This review examines how dysregulated protease activity contributes to viral entry, cytokine activation, vascular injury, and thrombosis. We focus on the integration of proteolytic systems such as the renin-angiotensin system, coagulation cascade, and neutrophil extracellular traps with established pathways like endothelial dysfunction and immune hyperactivation. Furthermore, we highlight therapeutic strategies aimed at restoring proteolytic balance and discuss the potential relevance of this paradigm in the management of long COVID.

摘要

自2019年末以来,由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引起的2019冠状病毒病(COVID-19)对全球健康产生了深远影响。除了呼吸道并发症外,该疾病还涉及由免疫失调、炎症和凝血病驱动的全身表现。在与重症相关的众多机制中,越来越多的证据表明蛋白酶和抗蛋白酶之间的失衡起着核心作用。本综述探讨了失调的蛋白酶活性如何导致病毒进入、细胞因子激活、血管损伤和血栓形成。我们重点关注诸如肾素-血管紧张素系统、凝血级联反应和中性粒细胞胞外陷阱等蛋白水解系统与内皮功能障碍和免疫过度激活等既定途径的整合。此外,我们强调旨在恢复蛋白水解平衡的治疗策略,并讨论这一模式在长期COVID管理中的潜在相关性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b99d/12341827/9925790f192b/IDR-18-3967-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b99d/12341827/9925790f192b/IDR-18-3967-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b99d/12341827/9925790f192b/IDR-18-3967-g0001.jpg

相似文献

1
COVID-19: A Disease Driven by Protease/Antiprotease Imbalance? A Specific Review Five Years into the Pandemic.新冠病毒病:一种由蛋白酶/抗蛋白酶失衡驱动的疾病?大流行五年后的专题综述
Infect Drug Resist. 2025 Aug 8;18:3967-3975. doi: 10.2147/IDR.S541205. eCollection 2025.
2
Systemic Inflammatory Response Syndrome全身炎症反应综合征
3
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
4
Measures implemented in the school setting to contain the COVID-19 pandemic.学校为控制 COVID-19 疫情而采取的措施。
Cochrane Database Syst Rev. 2022 Jan 17;1(1):CD015029. doi: 10.1002/14651858.CD015029.
5
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
6
Accuracy of routine laboratory tests to predict mortality and deterioration to severe or critical COVID-19 in people with SARS-CoV-2.常规实验室检测对预测 SARS-CoV-2 感染者死亡和病情恶化为重症或危重症 COVID-19 的准确性。
Cochrane Database Syst Rev. 2024 Aug 6;8(8):CD015050. doi: 10.1002/14651858.CD015050.pub2.
7
Profiling endogenous airway proteases and antiproteases and modeling proteolytic activation of Influenza HA using in vitro and ex vivo human airway surface liquid samples.使用体外和离体人呼吸道表面液体样本分析内源性气道蛋白酶和抗蛋白酶,并模拟流感血凝素的蛋白水解激活。
PLoS One. 2024 Dec 31;19(12):e0306197. doi: 10.1371/journal.pone.0306197. eCollection 2024.
8
Development of a new N-terminomic method to study the pathodegradome of the V8 protease in human neutrophils.开发一种新的N端蛋白质组学方法以研究人中性粒细胞中V8蛋白酶的降解组。
mSystems. 2025 Jun 25:e0069725. doi: 10.1128/msystems.00697-25.
9
Physical interventions to interrupt or reduce the spread of respiratory viruses.物理干预措施以阻断或减少呼吸道病毒的传播。
Cochrane Database Syst Rev. 2023 Jan 30;1(1):CD006207. doi: 10.1002/14651858.CD006207.pub6.
10
Active body surface warming systems for preventing complications caused by inadvertent perioperative hypothermia in adults.用于预防成人围手术期意外低温引起并发症的主动体表升温系统。
Cochrane Database Syst Rev. 2016 Apr 21;4(4):CD009016. doi: 10.1002/14651858.CD009016.pub2.

本文引用的文献

1
Comparison of Qanadli score with conventional risk stratifiers in non-massive pulmonary emboli.非大面积肺栓塞中 Qanadli 评分与传统危险分层因子的比较。
J Int Med Res. 2024 Sep;52(9):3000605241276481. doi: 10.1177/03000605241276481.
2
Bacterial Porins and Their Procoagulant Role: Implication in the Pathophysiology of Several Thrombotic Complications during Sepsis.细菌孔蛋白及其促凝作用:在脓毒症几种血栓并发症发病机制中的意义。
Toxins (Basel). 2024 Aug 20;16(8):368. doi: 10.3390/toxins16080368.
3
Cardiovascular disease and thrombosis: Intersections with the immune system, inflammation, and the coagulation system.
心血管疾病与血栓形成:与免疫系统、炎症及凝血系统的交叉关联
Ann Pharm Fr. 2025 Mar;83(2):228-250. doi: 10.1016/j.pharma.2024.08.005. Epub 2024 Aug 17.
4
Statin use and mortality in patients with deep vein thrombosis. Data from the RIETE Registry.他汀类药物在深静脉血栓形成患者中的应用与死亡率。来自 RIETE 登记处的数据。
Thromb Res. 2024 Apr;236:88-96. doi: 10.1016/j.thromres.2024.02.024. Epub 2024 Feb 24.
5
Anakinra or tocilizumab in patients admitted to hospital with severe covid-19 at high risk of deterioration (IMMCoVA): A randomized, controlled, open-label trial.阿那白滞素或托珠单抗治疗重症 COVID-19 高危恶化患者的疗效(IMMCoVA):一项随机、对照、开放标签试验。
PLoS One. 2023 Dec 29;18(12):e0295838. doi: 10.1371/journal.pone.0295838. eCollection 2023.
6
Interplay between COVID-19 and Secukinumab treatment in Spondylarthritis patients during the omicron surge: a retrospective cohort study.奥密克戎毒株激增期间,脊柱关节炎患者中新冠病毒19与司库奇尤单抗治疗之间的相互作用:一项回顾性队列研究
Autoimmunity. 2024 Dec;57(1):2281242. doi: 10.1080/08916934.2023.2281242. Epub 2023 Dec 13.
7
Statins Effects on Blood Clotting: A Review.他汀类药物对凝血的影响:综述。
Cells. 2023 Nov 27;12(23):2719. doi: 10.3390/cells12232719.
8
Involvement of Matrix Metalloproteinases in COVID-19: Molecular Targets, Mechanisms, and Insights for Therapeutic Interventions.基质金属蛋白酶在新型冠状病毒肺炎中的作用:分子靶点、机制及治疗干预见解
Biology (Basel). 2023 Jun 10;12(6):843. doi: 10.3390/biology12060843.
9
Comparative Analysis of Patients With STEMI and COVID-19 Between Canada and the United States.加拿大与美国ST段抬高型心肌梗死(STEMI)患者与新冠肺炎(COVID-19)患者的对比分析
J Soc Cardiovasc Angiogr Interv. 2023 Jun 21;2(5):100970. doi: 10.1016/j.jscai.2023.100970.
10
Efficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care in the treatment of patients hospitalized with moderate-to-critical COVID-19: A pilot randomized clinical trial (STRUCK: Survival Trial Using Cytokine Inhibitors).Ixekizumab 对比低剂量白细胞介素 2 对比秋水仙碱对比标准治疗用于治疗中重度 COVID-19 住院患者的疗效和安全性:一项先导随机临床试验(STRUCK:使用细胞因子抑制剂的生存试验)。
Rev Soc Bras Med Trop. 2023 Apr 14;56:e0565. doi: 10.1590/0037-8682-0565-2022. eCollection 2023.